Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,dividendsPaid,WC,language,region,quoteType,triggerable,quoteSourceName,currency,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingAnnualDividendRate,trailingPE,trailingAnnualDividendYield,epsTrailingTwelveMonths,epsForward,gmtOffSetMilliseconds,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,priceHint,shortName,longName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchange,market,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,exchangeDataDelayedBy,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,EUZ.DE,121745000,20590000,,,20399000,1145000,13749000,12706000,23854000,20138000,20138000,-8990000,-252000,,,,6586000,44160000,24022000,20306000,261000,,13813000,13749000,9808000,54334000,143401000,164730000,38903000,309276000,21172000,5892000,97471000,77198000,33177000,-8247000,10356000,95768000,46464000,9268000,4000,-2728000,60278000,179031000,16626000,1107000,38773000,1000,37491000,4847000,10310000.0,0.0,9865000.0,-728000.0,-882000.0,2226000.0,8291000.0,1027000.0,-1719000.0,2429000.0,834000.0,-3969000.0,-6292000.0,-154000.0,-9862000.0,-1279000.0,,132567000,en-US,US,EQUITY,False,Delayed Quote,EUR,-0.16207826,120.8 - 124.8,123.4,123.2,123.3,38,821,finmb_137792,XETRA,EUR,60488,59893,84.94,2.2200735,38.26 - 131.0,-7.800003,-0.059542008,38.26,131.0,1618570740,1628679540,1629115200,0.45,80.26059,0.0036466774,1.535,2.83,7200000,8.0,116.880554,6.3194427,0.05406753,87.29578,35.90422,2,ECKERT+ZIEGLER AG O.N.,Eckert & Ziegler Strahlen- und Medizintechnik AG,123.2,1630509955,-0.20000458,123.5,124.8,120.8,30186,POST,GER,de_market,0.4112939,2536687872,43.53357,15.4,15,Europe/Berlin,CEST,False,False,0,0.59,,,131.0,38.26,116.88,87.3,60.49k,59.89k,20.59M,,14.03M,30.98%,34.94%,,,,,,0.45,0.47%,0.45,0.36%,1.42,27.60%,,"Jun 03, 2021",4:1,"Jul 31, 2020","Dec 31, 2020","Mar 31, 2021",17.98%,26.93%,10.13%,20.49%,175.82M,8.54,-0.70%,86.53M,53.89M,31.61M,1.53,173.70%,96.88M,4.7,22.45M,13.54,3.85,8.00,30.32M,23.18M,Value,13125,Healthcare,843,7,5,"Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide. It operates through two segments, Medical and Isotope Products. The Medical segment offers small radioactive implants for the treatment of prostate cancer seeds; and eye application based on ruthenium-106 or iodine-125 for treating uveal melanoma. This segment provides radiopharmaceuticals, laboratory equipment, hot cells, and services for radiopharmaceuticals, as well as tumor irradiation equipment, eye applicators, and prostate implants. The Isotope Products segment manufactures and sells radiation sources for imaging, measurement technology, quality assurance, and environmental monitoring. This segment offers flood source, irradiation device, medical imaging source, ophthalmic applicator, quality control device, x-ray therapy device, and radiosynthesis system. The company was founded in 1992 and is headquartered in Berlin, Germany.",Berlin,49 30 94 10 84 0,7,1609372800,1625011200,10,Germany,http://www.ezag.com,86400,10,Robert-RÃ¶ssle-Strasse 10,49 30 94 10 84 112,Medical Devices
t-1,EUZ.DE,106405000,20590000,,,7134000,1096000,5160000,15662000,26755000,8882000,8882000,2211000,-351000,,,,1916000,49245000,40363000,22490000,-1748000,,5218000,5160000,8970000,54188000,143084000,147823000,28166000,292003000,21172000,18150000,83722000,76106000,32448000,-11259000,12987000,87475000,49124000,11898000,4000,-5740000,57861000,172842000,6895000,1135000,32508000,2000,33574000,5020000,-863000.0,0.0,-4049000.0,-989000.0,-1972000.0,-360000.0,12611000.0,-1198000.0,19830000.0,1404000.0,1500000.0,1877000.0,965000.0,-983000.0,9787000.0,-4014000.0,,123718000,en-US,US,EQUITY,False,Delayed Quote,EUR,-0.16207826,120.8 - 124.8,123.4,123.2,123.3,38,821,finmb_137792,XETRA,EUR,60488,59893,84.94,2.2200735,38.26 - 131.0,-7.800003,-0.059542008,38.26,131.0,1618570740,1628679540,1629115200,0.45,80.26059,0.0036466774,1.535,2.83,7200000,8.0,116.880554,6.3194427,0.05406753,87.29578,35.90422,2,ECKERT+ZIEGLER AG O.N.,Eckert & Ziegler Strahlen- und Medizintechnik AG,123.2,1630509955,-0.20000458,123.5,124.8,120.8,30186,POST,GER,de_market,0.4112939,2536687872,43.53357,15.4,15,Europe/Berlin,CEST,False,False,0,0.59,,,131.0,38.26,116.88,87.3,60.49k,59.89k,20.59M,,14.03M,30.98%,34.94%,,,,,,0.45,0.47%,0.45,0.36%,1.42,27.60%,,"Jun 03, 2021",4:1,"Jul 31, 2020","Dec 31, 2020","Mar 31, 2021",17.98%,26.93%,10.13%,20.49%,175.82M,8.54,-0.70%,86.53M,53.89M,31.61M,1.53,173.70%,96.88M,4.7,22.45M,13.54,3.85,8.00,30.32M,23.18M,Value,13125,Healthcare,843,7,5,"Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide. It operates through two segments, Medical and Isotope Products. The Medical segment offers small radioactive implants for the treatment of prostate cancer seeds; and eye application based on ruthenium-106 or iodine-125 for treating uveal melanoma. This segment provides radiopharmaceuticals, laboratory equipment, hot cells, and services for radiopharmaceuticals, as well as tumor irradiation equipment, eye applicators, and prostate implants. The Isotope Products segment manufactures and sells radiation sources for imaging, measurement technology, quality assurance, and environmental monitoring. This segment offers flood source, irradiation device, medical imaging source, ophthalmic applicator, quality control device, x-ray therapy device, and radiosynthesis system. The company was founded in 1992 and is headquartered in Berlin, Germany.",Berlin,49 30 94 10 84 0,7,1609372800,1625011200,10,Germany,http://www.ezag.com,86400,10,Robert-RÃ¶ssle-Strasse 10,49 30 94 10 84 112,Medical Devices
t-2,EUZ.DE,104963000,20590000,,,7345000,1018000,5031000,9990000,18860000,8135000,8135000,735000,-364000,,,,2303000,43273000,35138000,24413000,-790000,,5042000,5031000,8755000,38423000,134154000,146572000,38212000,281744000,21172000,20531000,94441000,68842000,32854000,-7464000,14643000,74864000,46154000,10197000,11000,-1509000,61857000,159225000,4410000,1041000,30256000,4000,32533000,4960000,-24000.0,0.0,-1721000.0,-691000.0,-210000.0,6677000.0,14031000.0,-423000.0,16385000.0,3091000.0,1500000.0,-2020000.0,4413000.0,481000.0,-807000.0,-1697000.0,,113071000,en-US,US,EQUITY,False,Delayed Quote,EUR,-0.16207826,120.8 - 124.8,123.4,123.2,123.3,38,821,finmb_137792,XETRA,EUR,60488,59893,84.94,2.2200735,38.26 - 131.0,-7.800003,-0.059542008,38.26,131.0,1618570740,1628679540,1629115200,0.45,80.26059,0.0036466774,1.535,2.83,7200000,8.0,116.880554,6.3194427,0.05406753,87.29578,35.90422,2,ECKERT+ZIEGLER AG O.N.,Eckert & Ziegler Strahlen- und Medizintechnik AG,123.2,1630509955,-0.20000458,123.5,124.8,120.8,30186,POST,GER,de_market,0.4112939,2536687872,43.53357,15.4,15,Europe/Berlin,CEST,False,False,0,0.59,,,131.0,38.26,116.88,87.3,60.49k,59.89k,20.59M,,14.03M,30.98%,34.94%,,,,,,0.45,0.47%,0.45,0.36%,1.42,27.60%,,"Jun 03, 2021",4:1,"Jul 31, 2020","Dec 31, 2020","Mar 31, 2021",17.98%,26.93%,10.13%,20.49%,175.82M,8.54,-0.70%,86.53M,53.89M,31.61M,1.53,173.70%,96.88M,4.7,22.45M,13.54,3.85,8.00,30.32M,23.18M,Value,13125,Healthcare,843,7,5,"Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide. It operates through two segments, Medical and Isotope Products. The Medical segment offers small radioactive implants for the treatment of prostate cancer seeds; and eye application based on ruthenium-106 or iodine-125 for treating uveal melanoma. This segment provides radiopharmaceuticals, laboratory equipment, hot cells, and services for radiopharmaceuticals, as well as tumor irradiation equipment, eye applicators, and prostate implants. The Isotope Products segment manufactures and sells radiation sources for imaging, measurement technology, quality assurance, and environmental monitoring. This segment offers flood source, irradiation device, medical imaging source, ophthalmic applicator, quality control device, x-ray therapy device, and radiosynthesis system. The company was founded in 1992 and is headquartered in Berlin, Germany.",Berlin,49 30 94 10 84 0,7,1609372800,1625011200,10,Germany,http://www.ezag.com,86400,10,Robert-RÃ¶ssle-Strasse 10,49 30 94 10 84 112,Medical Devices
t-3,EUZ.DE,90565000,20590000,,,10208000,1008000,7670000,11725000,19130000,10188000,10188000,-2783000,-235000,,,,2469000,39142000,28954000,20012000,20000,,7739000,7670000,8952000,53832000,125736000,141473000,32144000,268217000,5293000,4267000,89410000,70941000,41956000,-7062000,15159000,60833000,38086000,10475000,12000,-1543000,59084000,138226000,4840000,1093000,39009000,4000,33024000,3159000,-4381000.0,0.0,-5929000.0,-643000.0,-9542000.0,-1068000.0,-20010000.0,-365000.0,-4174000.0,2641000.0,1500000.0,-298000.0,-5539000.0,-148000.0,-7580000.0,-1729000.0,-8751000.0,100140000,en-US,US,EQUITY,False,Delayed Quote,EUR,-0.16207826,120.8 - 124.8,123.4,123.2,123.3,38,821,finmb_137792,XETRA,EUR,60488,59893,84.94,2.2200735,38.26 - 131.0,-7.800003,-0.059542008,38.26,131.0,1618570740,1628679540,1629115200,0.45,80.26059,0.0036466774,1.535,2.83,7200000,8.0,116.880554,6.3194427,0.05406753,87.29578,35.90422,2,ECKERT+ZIEGLER AG O.N.,Eckert & Ziegler Strahlen- und Medizintechnik AG,123.2,1630509955,-0.20000458,123.5,124.8,120.8,30186,POST,GER,de_market,0.4112939,2536687872,43.53357,15.4,15,Europe/Berlin,CEST,False,False,0,0.59,,,131.0,38.26,116.88,87.3,60.49k,59.89k,20.59M,,14.03M,30.98%,34.94%,,,,,,0.45,0.47%,0.45,0.36%,1.42,27.60%,,"Jun 03, 2021",4:1,"Jul 31, 2020","Dec 31, 2020","Mar 31, 2021",17.98%,26.93%,10.13%,20.49%,175.82M,8.54,-0.70%,86.53M,53.89M,31.61M,1.53,173.70%,96.88M,4.7,22.45M,13.54,3.85,8.00,30.32M,23.18M,Value,13125,Healthcare,843,7,5,"Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide. It operates through two segments, Medical and Isotope Products. The Medical segment offers small radioactive implants for the treatment of prostate cancer seeds; and eye application based on ruthenium-106 or iodine-125 for treating uveal melanoma. This segment provides radiopharmaceuticals, laboratory equipment, hot cells, and services for radiopharmaceuticals, as well as tumor irradiation equipment, eye applicators, and prostate implants. The Isotope Products segment manufactures and sells radiation sources for imaging, measurement technology, quality assurance, and environmental monitoring. This segment offers flood source, irradiation device, medical imaging source, ophthalmic applicator, quality control device, x-ray therapy device, and radiosynthesis system. The company was founded in 1992 and is headquartered in Berlin, Germany.",Berlin,49 30 94 10 84 0,7,1609372800,1625011200,10,Germany,http://www.ezag.com,86400,10,Robert-RÃ¶ssle-Strasse 10,49 30 94 10 84 112,Medical Devices
